{'fraction_non_alphanumeric': 0.057511737089201875, 'fraction_numerical': 0.03286384976525822, 'mean_word_length': 5.365671641791045, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis

Methods: The RESET trial (NCT02187003) was a phase 3, randomized, double-blind, controlled study of rivipansel for VOC requiring hospitalization. Three hundred forty-five patients (204 adults and 141 subjects 6-17 years old) were randomized to an intravenous rivipansel loading dose, followed by ≤14 additional doses Q 12 hr, or placebo, in addition to standard care. Overall, 162 were treated with rivipansel and 158 with placebo. The primary endpoint was time-to-readiness-for-discharge (TTRFD), and key secondary endpoints were time-to-discharge (TTD), time-to-discontinuation-of-IV-opioids (TTDIVO), and cumulative-IV-opioid-use (CIVO).